Chen Xueli, Dai Li
Pediatric department, Maternal and Child Health of Hubei Province, NO.745 Wuluo Road, Hongshan District, Wuhan, 430070, Hubei, People's Republic of China.
Biochem Genet. 2024 Oct 25. doi: 10.1007/s10528-024-10947-7.
Asthma is a common chronic respiratory disease in children, the incidence rate of which has increased in recent years. Wilms tumour 1-associated protein (WTAP) is an N6-methyladenosine (m6A) methyltransferase. The purpose of this study was to explore the specific mechanism of WTAP in asthma progression, and clarify the intricate interplay between m6A modifications, WTAP, AXIN1, and their collective impact on airway smooth muscle cells (ASMCs) proliferation in asthma. Platelet-derived growth factor-BB (PDGF-BB)-treated ASMCs were used to establish an asthma model in vitro. The cell phenotype was tested using CCK-8, transwell, and wound healing assays. The expression of the Wnt signalling pathway was detected by western blotting. In addition, the relationship between WTAP/YTDHF2 and AXIN1 was assessed by a double luciferase reporter assay. Actinomycin D treatment and RT‒qPCR assays were performed to determine the mRNA stability of AXIN1. We found that WTAP was significantly increased in PDGF-BB-treated ASMCs. Knockdown of WTAP inhibited the excessive cell viability and migration of ASMCs induced by PDGF-BB. Furthermore, WTAP knockdown increased AXIN1 levels and inhibited the Wnt signalling pathway. Furthermore, WTAP knockdown decreased the m6A levels and enhanced the mRNA stability of AXIN1. WTAP overexpression showed the opposite effect. In addition, YTHDF2 was demonstrated to be the reader that recognizes the WTAP-mediated m6A modification of AXIN1. YTHDF2 knockdown enhanced the mRNA stability of AXIN1 and reversed the effect of WTAP overexpression on PDGF-BB-treated ASMCs. WTAP knockdown inhibited the excessive cell viability and migration of ASMCs by enhancing the m6A levels of AXIN1, which was further recognized by YTHDF2. The upregulation of AXIN1 mediated by the WTAP/YTHDF2 axis further inhibited the Wnt signalling pathway. Our study provides a new method for the treatment of asthma. This work not only deepens our understanding of the molecular underpinnings of asthma but also identifies potential therapeutic targets for the development of novel treatments aimed at inhibiting ASMC proliferation and alleviating asthma symptoms.
哮喘是儿童常见的慢性呼吸道疾病,近年来其发病率有所上升。肾母细胞瘤1相关蛋白(WTAP)是一种N6-甲基腺苷(m6A)甲基转移酶。本研究的目的是探讨WTAP在哮喘进展中的具体机制,并阐明m6A修饰、WTAP、AXIN1之间复杂的相互作用,以及它们对哮喘气道平滑肌细胞(ASMCs)增殖的共同影响。使用血小板衍生生长因子-BB(PDGF-BB)处理的ASMCs在体外建立哮喘模型。通过CCK-8、transwell和伤口愈合试验检测细胞表型。通过蛋白质印迹法检测Wnt信号通路的表达。此外,通过双荧光素酶报告基因试验评估WTAP/YTDHF2与AXIN1之间的关系。进行放线菌素D处理和RT-qPCR试验以确定AXIN1的mRNA稳定性。我们发现,在PDGF-BB处理的ASMCs中WTAP显著增加。敲低WTAP可抑制PDGF-BB诱导的ASMCs过度的细胞活力和迁移。此外,敲低WTAP可增加AXIN1水平并抑制Wnt信号通路。此外,敲低WTAP可降低m6A水平并增强AXIN1的mRNA稳定性。WTAP过表达则显示出相反的效果。此外,YTHDF2被证明是识别WTAP介导的AXIN1的m6A修饰的读取蛋白。敲低YTHDF2可增强AXIN1的mRNA稳定性,并逆转WTAP过表达对PDGF-BB处理的ASMCs的影响。敲低WTAP通过增强AXIN1的m6A水平来抑制ASMCs过度的细胞活力和迁移,而AXIN1的m6A水平会被YTHDF2进一步识别。由WTAP/YTHDF2轴介导的AXIN1上调进一步抑制了Wnt信号通路。我们的研究为哮喘治疗提供了一种新方法。这项工作不仅加深了我们对哮喘分子基础的理解,还确定了潜在的治疗靶点,以开发旨在抑制ASMC增殖和缓解哮喘症状的新型治疗方法。